Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Locoregional Chemoimmunotherapy, αDC1 Vaccines, and Pembrolizumab for Advanced Ovarian Cancer
NCT07634094Phase 2Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of alpha-type-1-polarized dendritic cell vaccine in ovarian cancer. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
alpha-type-1-polarized dendritic cell vaccine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07634094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07634094.